Harmony Biosciences Holdings, Inc. (HRMY) — SEC Filings

Latest SEC filings for Harmony Biosciences Holdings, Inc. (HRMY), explained in plain English.

Sentiment Overview: 2 bullish, 30 neutral

Recent Filings (32)

• Harmony Biosciences Files Annual Report for 2025 — ARS · 2026-04-03T08:10:08-04:00 [neutral] Risk: low
  Harmony Biosciences Holdings, Inc. filed its Annual Report to Security Holders (ARS) on April 3, 2026, for the period ending December 31, 2025. The filing inclu
• Harmony Biosciences Files Proxy Materials — DEFA14A · 2026-04-03T08:05:05-04:00 [neutral] Risk: low
  Harmony Biosciences Holdings, Inc. filed a DEFA14A on April 3, 2026, which contains additional definitive proxy soliciting materials. The filing includes three
• Harmony Biosciences Soars on Strong WAKIX Sales, Strategic Acquisitions — 10-Q · 2025-11-04T00:00:00.000Z [bullish] Risk: medium
  Harmony Biosciences Holdings, Inc. (HRMY) reported robust financial performance for the nine months ended September 30, 2025, with net product revenue increasin
• Harmony Biosciences Files 8-K on Financials — 8-K · 2025-10-23T00:00:00.000Z [neutral] Risk: low
  Harmony Biosciences Holdings, Inc. filed an 8-K on October 23, 2025, reporting on its results of operations and financial condition. The filing includes financi
• Harmony Biosciences Files 8-K — 8-K · 2025-09-24T00:00:00.000Z [neutral] Risk: low
  Harmony Biosciences Holdings, Inc. filed an 8-K on September 24, 2025, reporting information under Regulation FD Disclosure and Financial Statements and Exhibit
• Harmony Biosciences' WAKIX Sales Drive Strong Q2 Growth — 10-Q · 2025-08-05T00:00:00.000Z [bullish] Risk: medium
  Harmony Biosciences Holdings, Inc. reported strong financial performance for the quarter ended June 30, 2025, driven primarily by increased WAKIX sales. Revenue
• Harmony Biosciences Files 8-K — 8-K · 2025-06-11T00:00:00.000Z [neutral] Risk: low
  Harmony Biosciences Holdings, Inc. filed an 8-K on June 11, 2025, reporting on Regulation FD disclosures and financial statements. The filing does not contain s
• Harmony Biosciences Files 8-K — 8-K · 2025-06-05T00:00:00.000Z [neutral] Risk: low
  Harmony Biosciences Holdings, Inc. filed an 8-K on June 5, 2025, reporting on other events and financial statements. The filing details the company's principal
• Harmony Biosciences Files 8-K on Shareholder Vote Matters — 8-K · 2025-05-15T00:00:00.000Z [neutral] Risk: low
  Harmony Biosciences Holdings, Inc. filed an 8-K on May 15, 2025, to report on matters submitted to a vote of its security holders. The filing does not contain d
• Harmony Biosciences Files Q1 2025 10-Q — 10-Q · 2025-05-06T00:00:00.000Z [neutral] Risk: medium
  Harmony Biosciences Holdings, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported financial results and provided updates on its busin
• Harmony Biosciences Files Definitive Proxy Statement — DEF 14A · 2025-04-04T00:00:00.000Z [neutral] Risk: low
  Harmony Biosciences Holdings, Inc. filed a Definitive Proxy Statement (DEF 14A) on April 4, 2025, for its annual meeting on May 15, 2025. The filing concerns th
• Harmony Biosciences Files 8-K: Director/Officer Changes & Compensation — 8-K · 2025-04-03T00:00:00.000Z [neutral] Risk: low
  Harmony Biosciences Holdings, Inc. filed an 8-K on April 3, 2025, reporting changes in directors and officers, and compensatory arrangements. The filing also in
• Harmony Biosciences Reports Officer/Director Changes & Compensation — 8-K · 2025-03-24T00:00:00.000Z [neutral] Risk: medium
  Harmony Biosciences Holdings, Inc. filed an 8-K on March 24, 2025, reporting events as of March 20, 2025. The filing primarily concerns the departure of directo
• Harmony Biosciences Files 2024 Annual Report — 10-K · 2025-02-25T00:00:00.000Z [neutral] Risk: medium
  Harmony Biosciences Holdings, Inc. filed its 2024 10-K on February 25, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. T
• Harmony Biosciences Files 8-K on Financials — 8-K · 2025-01-13T00:00:00.000Z [neutral] Risk: low
  Harmony Biosciences Holdings, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also includes Re
• Harmony Biosciences Files 8-K — 8-K · 2024-11-01T00:00:00.000Z [neutral] Risk: low
  Harmony Biosciences Holdings, Inc. filed an 8-K on November 1, 2024, reporting an event that occurred on October 30, 2024. The filing pertains to 'Other Events'
• Harmony Biosciences Q3 2024 10-Q Filing — 10-Q · 2024-10-29T00:00:00.000Z [neutral] Risk: medium
  Harmony Biosciences Holdings, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial results and provided updates on i
• 8-K Filing — 8-K · 2024-10-01T00:00:00.000Z [neutral]
• Harmony Biosciences Files Q2 2024 10-Q — 10-Q · 2024-08-06T00:00:00.000Z [neutral] Risk: medium
  Harmony Biosciences Holdings, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial performance and business operations. K
• Harmony Biosciences Announces Executive Appointments and Departures — 8-K · 2024-07-01T00:00:00.000Z [neutral] Risk: medium
  Harmony Biosciences Holdings, Inc. announced on June 27, 2024, a series of executive changes. Dr. Jeffrey M. Dayno has been appointed Chief Medical Officer, and
• Harmony Biosciences Files 8-K on Shareholder Vote Matters — 8-K · 2024-05-29T00:00:00.000Z [neutral] Risk: low
  Harmony Biosciences Holdings, Inc. filed an 8-K on May 29, 2024, to report on matters submitted to a vote of its security holders. The filing does not detail th
• Harmony Biosciences Reports Officer/Director Changes & Compensatory Info — 8-K · 2024-05-03T00:00:00.000Z [neutral] Risk: medium
  Harmony Biosciences Holdings, Inc. filed an 8-K on May 3, 2024, reporting events as of May 1, 2024. The filing primarily concerns the departure of directors or
• Harmony Biosciences Q1 2024 Update — 10-Q · 2024-04-30T00:00:00.000Z [neutral] Risk: medium
  Harmony Biosciences Holdings, Inc. reported its first quarter 2024 results, ending March 31, 2024. The company's filing details its financial performance and op
• Harmony Biosciences Files Proxy Statement for Annual Meeting — DEF 14A · 2024-04-11T00:00:00.000Z [neutral] Risk: low
  Harmony Biosciences Holdings, Inc. filed a definitive proxy statement (DEF 14A) on April 11, 2024, for its annual meeting on May 29, 2024. The filing concerns t
• Harmony Biosciences Enters Material Definitive Agreement — 8-K · 2024-04-11T00:00:00.000Z [neutral] Risk: medium
  Harmony Biosciences Holdings, Inc. announced on April 6, 2024, the entry into a material definitive agreement. The company, incorporated in Delaware with IRS nu
• Harmony Biosciences Amends 2023 10-K for Executive Compensation Details — 10-K/A · 2024-02-28T00:00:00.000Z [neutral] Risk: low
  Harmony Biosciences Holdings, Inc. filed a Form 10-K/A on February 28, 2024, amending its annual report for the fiscal year ended December 31, 2023. The amendme
• Harmony Biosciences Files 2023 10-K — 10-K · 2024-02-22T00:00:00.000Z [neutral] Risk: medium
  Harmony Biosciences Holdings, Inc. filed its 10-K on February 22, 2024, for the fiscal year ended December 31, 2023. The company, a pharmaceutical preparations
• SC 13G/A Filing — SC 13G/A · 2024-02-13T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-02-13T00:00:00.000Z [neutral]
• FMR LLC & Abigail Johnson Disclose 9.009% Stake in Harmony Bio — SC 13G/A · 2024-02-09T00:00:00.000Z [neutral] Risk: low
  FMR LLC, a major investment firm, and its principal owner, Abigail P. Johnson, have updated their ownership stake in Harmony Biosciences Holdings, Inc. (NASDAQ:
• BlackRock Amends Harmony Bio Stake, Holds 5.47M Shares — SC 13G/A · 2024-01-24T00:00:00.000Z [neutral]
  BlackRock Inc. filed an amended Schedule 13G/A on January 24, 2024, disclosing its ownership in Harmony Biosciences Holdings, Inc. As of December 31, 2023, Blac
• Harmony Biosciences Files 8-K on Financial Condition — 8-K · 2024-01-08T00:00:00.000Z [neutral]
  Harmony Biosciences Holdings, Inc. filed an 8-K on January 8, 2024, to report on its results of operations and financial condition. This filing, under the Secur